Search - tctmd.com

Displaying 681 - 700 of 713

Sort: Relevancy | Date

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

News Daily News

Danish Study Looks at Impact of Socioeconomic Status on Primary PCI Outcomes

Caitlin E. Cox

October 09, 2012

Presentation

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Presenter: Andr?s Kom?csi

October 01, 2012

Presentation ESC 2012

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

Presenter: 205474|Benjamin Scirica

August 26, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Conference News ESC 2012

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

Caitlin E. Cox

August 26, 2012

News Daily News

Infection After Primary PCI Rare but Serious

August 07, 2012

News Daily News

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

Presentation TCT 2012

The Utility of Three Primary Prevention Scoring Systems (Framingham, PROCAM, and SCORE) in Predicting Future Events in Patients with Acute Coronary Syndromes: The PROSPECT Trial

Presenter: Jung-Won Suh, Gary S. Mintz, Giora Weisz, Akiko Maehara, Ke Xu, Alexandra J. Lansky, Ecaterina Cristea, Roxana Mehran, John McPherson, Naim Farhat, Steven P. Marso, Bernard de Bruyne, Patrick W. Serruys, Gregg W. Stone

January 03, 2012

News Conference News

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

November 15, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Daily News

Antiplatelet Therapy Plus SSRI Spurs Bleeding After MI

Yael L. Maxwell

September 26, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Conference News

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

September 01, 2011

News Conference News

Halting Clopidogrel in First Year Following Acute MI Hazardous

September 01, 2011

Advertisement

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Evidence Continues to Support Dabigatran Treatment in A-fib

Danish Study Looks at Impact of Socioeconomic Status on Primary PCI Outcomes

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

Infection After Primary PCI Rare but Serious

More Than Half of Readmissions Within 30 Days of Acute MI Unrelated to Index Event

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

The Utility of Three Primary Prevention Scoring Systems (Framingham, PROCAM, and SCORE) in Predicting Future Events in Patients with Acute Coronary Syndromes: The PROSPECT Trial

MI FREEE: Free Post-MI Drugs Reduce Events, Costs

Hope Renewed for Novel Anticoagulant Use in ACS

Antiplatelet Therapy Plus SSRI Spurs Bleeding After MI

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

Halting Clopidogrel in First Year Following Acute MI Hazardous

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content